Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 12 studies | 27% ± 11% | |
ciliated cell | 11 studies | 25% ± 8% | |
oligodendrocyte precursor cell | 10 studies | 26% ± 11% | |
CD4-positive, alpha-beta T cell | 9 studies | 18% ± 3% | |
microglial cell | 8 studies | 26% ± 9% | |
naive thymus-derived CD4-positive, alpha-beta T cell | 7 studies | 20% ± 4% | |
fibroblast | 7 studies | 20% ± 5% | |
B cell | 7 studies | 18% ± 4% | |
neutrophil | 6 studies | 32% ± 12% | |
interneuron | 6 studies | 31% ± 21% | |
epithelial cell | 6 studies | 41% ± 17% | |
retinal cone cell | 6 studies | 30% ± 10% | |
astrocyte | 6 studies | 30% ± 10% | |
macrophage | 6 studies | 27% ± 9% | |
oligodendrocyte | 6 studies | 24% ± 6% | |
monocyte | 5 studies | 19% ± 4% | |
neuron | 5 studies | 32% ± 12% | |
naive B cell | 5 studies | 18% ± 3% | |
myeloid cell | 5 studies | 22% ± 3% | |
retinal rod cell | 5 studies | 25% ± 6% | |
dendritic cell | 5 studies | 24% ± 10% | |
abnormal cell | 5 studies | 24% ± 11% | |
GABAergic neuron | 5 studies | 39% ± 16% | |
glutamatergic neuron | 5 studies | 45% ± 21% | |
classical monocyte | 4 studies | 24% ± 3% | |
natural killer cell | 4 studies | 17% ± 2% | |
pericyte | 4 studies | 21% ± 7% | |
basal cell | 4 studies | 36% ± 23% | |
CD4-positive, alpha-beta memory T cell | 4 studies | 24% ± 4% | |
memory B cell | 4 studies | 17% ± 0% | |
hematopoietic precursor cell | 3 studies | 23% ± 4% | |
granule cell | 3 studies | 17% ± 1% | |
lymphocyte | 3 studies | 26% ± 3% | |
type I pneumocyte | 3 studies | 19% ± 3% | |
effector memory CD4-positive, alpha-beta T cell | 3 studies | 21% ± 1% | |
endothelial cell of lymphatic vessel | 3 studies | 25% ± 6% | |
smooth muscle cell | 3 studies | 17% ± 2% | |
goblet cell | 3 studies | 32% ± 21% | |
transit amplifying cell | 3 studies | 42% ± 26% | |
central memory CD4-positive, alpha-beta T cell | 3 studies | 21% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 3108.80 | 459 / 459 | 100% | 58.17 | 1118 / 1118 |
esophagus | 100% | 3346.25 | 1445 / 1445 | 100% | 74.74 | 183 / 183 |
intestine | 100% | 3521.79 | 966 / 966 | 100% | 57.96 | 527 / 527 |
ovary | 100% | 2920.65 | 180 / 180 | 100% | 47.64 | 430 / 430 |
stomach | 100% | 2593.58 | 359 / 359 | 100% | 60.22 | 286 / 286 |
bladder | 100% | 3472.33 | 21 / 21 | 100% | 51.75 | 503 / 504 |
prostate | 100% | 3569.47 | 245 / 245 | 100% | 54.15 | 501 / 502 |
lung | 100% | 3056.98 | 577 / 578 | 100% | 53.50 | 1154 / 1155 |
kidney | 100% | 2677.91 | 89 / 89 | 100% | 46.48 | 898 / 901 |
brain | 100% | 2694.94 | 2632 / 2642 | 100% | 61.95 | 705 / 705 |
thymus | 100% | 2848.00 | 653 / 653 | 99% | 47.99 | 600 / 605 |
skin | 100% | 4053.86 | 1809 / 1809 | 99% | 56.57 | 468 / 472 |
uterus | 100% | 3366.86 | 170 / 170 | 99% | 51.62 | 455 / 459 |
pancreas | 99% | 1529.25 | 326 / 328 | 99% | 39.54 | 177 / 178 |
liver | 100% | 2033.41 | 226 / 226 | 97% | 26.61 | 392 / 406 |
adrenal gland | 100% | 3302.78 | 258 / 258 | 96% | 31.89 | 221 / 230 |
adipose | 100% | 2954.27 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2892.34 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 59.58 | 29 / 29 |
muscle | 100% | 4639.72 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3953.52 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 48.65 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 31.20 | 1 / 1 |
peripheral blood | 100% | 6988.18 | 926 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 33.96 | 78 / 80 |
heart | 96% | 2257.91 | 828 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006974 | Biological process | DNA damage response |
GO_0071347 | Biological process | cellular response to interleukin-1 |
GO_0035520 | Biological process | monoubiquitinated protein deubiquitination |
GO_0072344 | Biological process | rescue of stalled ribosome |
GO_0010506 | Biological process | regulation of autophagy |
GO_0006508 | Biological process | proteolysis |
GO_0016579 | Biological process | protein deubiquitination |
GO_0006914 | Biological process | autophagy |
GO_0019985 | Biological process | translesion synthesis |
GO_0043124 | Biological process | negative regulation of canonical NF-kappaB signal transduction |
GO_0030330 | Biological process | DNA damage response, signal transduction by p53 class mediator |
GO_0062030 | Biological process | negative regulation of stress granule assembly |
GO_0022626 | Cellular component | cytosolic ribosome |
GO_0005769 | Cellular component | early endosome |
GO_0032991 | Cellular component | protein-containing complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0045111 | Cellular component | intermediate filament cytoskeleton |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0004843 | Molecular function | cysteine-type deubiquitinase activity |
GO_0002039 | Molecular function | p53 binding |
GO_0044325 | Molecular function | transmembrane transporter binding |
GO_0003723 | Molecular function | RNA binding |
GO_0140678 | Molecular function | molecular function inhibitor activity |
GO_0004197 | Molecular function | cysteine-type endopeptidase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | USP10 |
Protein name | Ubiquitin carboxyl-terminal hydrolase 10 (EC 3.4.19.12) (Deubiquitinating enzyme 10) (Ubiquitin thioesterase 10) (Ubiquitin-specific-processing protease 10) Ubiquitin specific peptidase 10 ubiquitinyl hydrolase 1 (EC 3.4.19.12) |
Synonyms | DKFZp686E14181 KIAA0190 |
Description | FUNCTION: Hydrolase that can remove conjugated ubiquitin from target proteins such as p53/TP53, RPS2/us5, RPS3/us3, RPS10/eS10, BECN1, SNX3 and CFTR . Acts as an essential regulator of p53/TP53 stability: in unstressed cells, specifically deubiquitinates p53/TP53 in the cytoplasm, leading to counteract MDM2 action and stabilize p53/TP53 . Following DNA damage, translocates to the nucleus and deubiquitinates p53/TP53, leading to regulate the p53/TP53-dependent DNA damage response . Component of a regulatory loop that controls autophagy and p53/TP53 levels: mediates deubiquitination of BECN1, a key regulator of autophagy, leading to stabilize the PIK3C3/VPS34-containing complexes . In turn, PIK3C3/VPS34-containing complexes regulate USP10 stability, suggesting the existence of a regulatory system by which PIK3C3/VPS34-containing complexes regulate p53/TP53 protein levels via USP10 and USP13 . Does not deubiquitinate MDM2 . Plays a key role in 40S ribosome subunit recycling when a ribosome has stalled during translation: acts both by inhibiting formation of stress granules, which store stalled translation pre-initiation complexes, and mediating deubiquitination of 40S ribosome subunits . Acts as a negative regulator of stress granules formation by lowering G3BP1 and G3BP2 valence, thereby preventing G3BP1 and G3BP2 ability to undergo liquid-liquid phase separation (LLPS) and assembly of stress granules . Promotes 40S ribosome subunit recycling following ribosome dissociation in response to ribosome stalling by mediating deubiquitination of 40S ribosomal proteins RPS2/us5, RPS3/us3 and RPS10/eS10, thereby preventing their degradation by the proteasome . Part of a ribosome quality control that takes place when ribosomes have stalled during translation initiation (iRQC): USP10 acts by removing monoubiquitination of RPS2/us5 and RPS3/us3, promoting 40S ribosomal subunit recycling . Deubiquitinates CFTR in early endosomes, enhancing its endocytic recycling . Involved in a TANK-dependent negative feedback response to attenuate NF-kappa-B activation via deubiquitinating IKBKG or TRAF6 in response to interleukin-1-beta (IL1B) stimulation or upon DNA damage . Deubiquitinates TBX21 leading to its stabilization . Plays a negative role in the RLR signaling pathway upon RNA virus infection by blocking the RIGI-mediated MAVS activation. Mechanistically, removes the unanchored 'Lys-63'-linked polyubiquitin chains of MAVS to inhibit its aggregation, essential for its activation . . |
Accessions | H3BVF1 H3BNA1 ENST00000563048.5 ENST00000567526.1 H3BNS8 ENST00000219473.12 [Q14694-1] H3BQP1 ENST00000569925.1 ENST00000540269.6 ENST00000563386.5 ENST00000570053.1 J3KT19 H3BNP1 Q6P2I0 ENST00000569038.5 Q68D90 H3BNL0 ENST00000563892.5 H3BQC6 ENST00000562283.5 ENST00000570191.5 [Q14694-3] Q14694 |